Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.58 |
| ▸ | ACLY | P53396 | 3/20 | 0.49 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889391 | 0.85 | TRPV4 (0.63) | TRPV4ACLYRAD51SLC22A12HSD11B1 | |
| SCHEMBL30033203 | 0.85 | TRPV4 (0.63) | TRPV4ACLYRAD51SLC22A12HSD11B1 | |
| SCHEMBL31296510 | 0.81 | ACLY (0.49) | TRPV4ACLYRAD51SGK1CA1 | |
| SCHEMBL15412234 | 0.81 | ACLY (0.49) | TRPV4ACLYRAD51TBXA2R | |
| SCHEMBL2778205 | 0.81 | ACLY (0.49) | TRPV4ACLYRAD51SGK1CA1 | |
| SCHEMBL31461007 | 0.79 | TRPV4 (0.56) | TRPV4RAD51SLC22A12HSD11B1CA1 | |
| SCHEMBL1942524 | 0.79 | TRPV4 (0.56) | TRPV4RAD51SLC22A12HSD11B1CA1 | |
| SCHEMBL697280 | 0.78 | SLC22A12 (0.46) | TRPV4SLC22A12TBXA2R | |
| SCHEMBL3079216 | 0.78 | TRPV4 (0.54) | TRPV4RAD51PIK3CDPIK3CASGK1 | |
| SCHEMBL22499600 | 0.77 | ALDH1A1 (0.47) | TRPV4ACLYRAD51PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558481-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-15 | — | — | US | disclosed |
| CN-119855809-A | Emopanamide binding protein inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119731156-A | Emopanamide binding protein inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119264303-A | Pendant group functionalized fluorine-containing polymer, preparation method of fluorine-containing polymer, ion exchange membrane and application | 佛山绿动氢能科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4479384-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-3865472-B1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LTD (IE) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024020156-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20140357640-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140288083-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-09-25 | — | — | US | disclosed |
| EP-2758399-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013041119-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013041502-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-28 | — | — | WO | disclosed |
| US-20130072493-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| EP-2570415-A1 | N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2013-03-20 | — | — | EP | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072493-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | TRPV4 817/4885ACLY 2482/4885RAD51 3618/4885 |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | TRPV4 4085/4885ACLY 2601/4885RAD51 433/4885 |
| US-20140357640-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK3, SGK1, SGK2 | TRPV4 1001/4885ACLY 2363/4885RAD51 3549/4885 |
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | TRPV4 4560/4885ACLY 3232/4885RAD51 2517/4885 |
| US-20140288083-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | TRPV4 817/4885ACLY 2482/4885RAD51 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.